HTR6 and Alzheimer disease: Indeed, several 5-HT6R antagonists have advanced to clinical development, and to date, at least three of them have reached phase II/III trials as drug candidates for cognitive enhancement, which holds promise for these compounds as novel therapeutic agents for the treatment of Alzheimer’s disease (AD)5.